Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length

被引:84
作者
Cooper, AJL
Sheu, KFR
Burke, JR
Onodera, O
Stritmatter, WJ
Roses, AD
Blass, JP
机构
[1] CORNELL UNIV,DEPT BIOCHEM,COLL MED,NEW YORK,NY 10021
[2] CORNELL UNIV,DEPT NEUROL & NEUROSCI,COLL MED,NEW YORK,NY 10021
[3] CORNELL UNIV,DEPT MED,COLL MED,NEW YORK,NY 10021
[4] DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710
[5] DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710
[6] DUKE UNIV,MED CTR,DEANE LAB,DURHAM,NC 27710
关键词
D O I
10.1073/pnas.94.23.12604
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Several adult-onset neurodegenerative diseases are caused by genes with expanded CAG triplet repeats within their coding regions and extended polyglutamine (a) domains within the expressed proteins. Generally, in clinically affected individuals n greater than or equal to 40. Glyceraldehyde 3-phosphate dehydrogenase binds tightly to four Q(n) disease proteins, but the significance of this interaction is unknown. We now report that purified glyceraldehyde 3-phosphate dehydrogenase is inactivated by tissue transglutaminase in the presence of glutathione S-transferase constructs containing a a domain of pathological length (n = 62 or 81). The dehydrogenase is less strongly inhibited by tissue transglutaminase in the presence of constructs containing shorter Q(n) domains (n = 0 or 10). Purified cr-ketoglutarate dehydrogenase complex also is inactivated by tissue transglutaminase plus glutathione S-transferase constructs containing pathological-length a domains (n = 62 or 81). The results suggest that tissue transglutaminase-catalyzed covalent linkages involving the larger poly-Q domains may disrupt cerebral energy metabolism in CAG/Q(n) expansion diseases.
引用
收藏
页码:12604 / 12609
页数:6
相关论文
共 58 条
  • [1] AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402
  • [2] THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE
    ANDREW, SE
    GOLDBERG, YP
    KREMER, B
    TELENIUS, H
    THEILMANN, J
    ADAM, S
    STARR, E
    SQUITIERI, F
    LIN, BY
    KALCHMAN, MA
    GRAHAM, RK
    HAYDEN, MR
    [J]. NATURE GENETICS, 1993, 4 (04) : 398 - 403
  • [3] AGING, ENERGY, AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
    BEAL, MF
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (03) : 357 - 366
  • [4] STIMULATION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE MESSENGER-RNA LEVELS BY ENDOGENOUS NITRIC-OXIDE IN CYTOKINE-ACTIVATED ENDOTHELIUM
    BERETA, J
    BERETA, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 217 (01) : 363 - 369
  • [5] BERGMEYER HU, 1974, METHOD ENZYMAT AN, P2267
  • [6] THE IDENTIFICATION OF A FUNCTIONAL NUCLEAR-LOCALIZATION SIGNAL IN THE HUNTINGTON DISEASE PROTEIN
    BESSERT, DA
    GUTRIDGE, KL
    DUNBAR, JC
    CARLOCK, LR
    [J]. MOLECULAR BRAIN RESEARCH, 1995, 33 (01): : 165 - 173
  • [7] BLASS JP, 1991, REV NEUROL, V147, P513
  • [8] BLASS JP, 1993, HIPPOCAMPUS, V3, P45
  • [9] BLASS JP, 1996, ALZHEIMERS DIS CAUSE, P187
  • [10] BOLLAG DM, 1991, PROTEIN METHODS, P181